Phenotypic Heterogeneity in Hemophilia A: An Investigation of the Role of Platelet Function

Completed

• Conditions: Hemophilia A

• Registration Number: NCT02225483
• Lead Sponsor: CancerCare Manitoba

Brief Summary

The is study will examine whether variation in clinical bleeding frequency and severity among boys with severe Hemophilia A (Factor VIII deficiency) is associated with variations in laboratory measurements of platelet activity.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2014-08-25
• Study First Submitted QC: 2014-08-25
• Study First Posted: 2014-08-26
• Study Start: 2014-09
• Primary Completion: 2015-12
• Status Verified: 2016-01
• Study Completion: 2016-12
• Last Update Submitted: 2017-02-02
• Last Update Posted: 2017-02-03

Recruitment & Eligibility

• Status: COMPLETED
• Sex: Male
• Target Recruitment: 42

Inclusion Criteria

• documented circulating FVIII level of ≤1%
• age 3 - 20 years
• may be on primary or secondary prophylaxis
• granting of informed consent

Exclusion Criteria

• measurable inhibitor level at the time of enrollment
• ingestion of aspirin/supplement known to influence platelet function within 14 days of blood sampling, or ibuprofen within 3 days

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Procoagulant platelet-derived microparticle formation	At time of enrollment
Platelet aggregation	At time of enrollment	Whole blood platelet aggregation responses

Trial Locations

Locations (2)

The Hospital for Sick Children; 🇨🇦 Toronto, Ontario, Canada

CancerCare Manitoba; 🇨🇦 Winnipeg, Manitoba, Canada